Skip to content

Beschikbaarheid van uridine in het bloed van gezonde ouderen na eenmalige inname van een nucleotide en een alternatief ingrediënt.

Bioequivalence of uridine bioavailability in healthy elderly after bolus intake of a nucleotide and an alternative ingredient.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON24695
Enrollment
25
Registered
2015-07-06
Start date
2015-07-20
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bioequivalence

Interventions

After an overnight fast, subjects will ingest one dosage of one of the five study products at each study visit (except during screening).

Sponsors

Nutricia Research B.V., Utrecht, The Netherlands
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Healthy volunteers 2. Age 60 years or older 3. BMI from 20 through 30 kg/m2

Exclusion criteria

Exclusion criteria: 1. Any condition that may interfere with the definition ‘healthy volunteer’ according to the investigator, with special attention to the presence of liver and renal disease, diabetes mellitus, Alzheimer, diarrhea, obstipation and known severe weight loss (> 3 kg in last 3 months) 2. Any gastrointestinal (GI) disease or surgery that interferes with GI function 3. (History of) any cancer with the exception of basal cell carcinoma 4. Any sign of inflammation in the last 7 days prior to Visit 1

Design outcomes

Primary

MeasureTime frame
The primary outcome parameters in this study are Urd AUC [ìmol/L*min] and Cmax [ìmol/L] (product B versus A).

Secondary

MeasureTime frame
The secondary outcome parameters in this study are Urd AUC [ìmol/L*min] and Cmax [ìmol/L], Tmax [min] and t½ AUC [min] , Urd AUC [ìmol/L*min], Cmax [ìmol/L], Tmax [min] and t½ AUC [min].

Contacts

Public ContactA. van Helvoort

Nutricia Research

Email: A.vanHelvoort@nutricia.comTel. +31-30-2095000

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)